AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05305066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-IL6
Description: Anti-IL6 receptor monoclonal antibodies - tocilizumab (if weight \<100 kg: 162 mg SC every other week, followed by an increase to weekly based on clinical response; if weight ≥100 kg: 162 mg SC weekly) or sarilumab (200 mg SC once every 2 weeks)
Study NCT05305066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JAKi
Description: JAKi - tofacitinib (JAK1/3 inhibitor) 5 mg po bid, baricitinib 2 mg po qd (JAK 1/2 inhibitor) or upadacitinib 15 mg po qd (JAK1 inhibitor)
Study NCT05677035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LINO-1713 1 tablet
Description: LINO-1713 1 tablet is administered once. Oral administration with 200mL of water
Study NCT05677035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LINO-1713 once a day for 24 days
Description: Oral administration is performed with 200 mL of water. Instruct subjects to take the drug at the same time as possible.
Study NCT05288439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Resting-state functional connectivity MRI
Description: participants will undergo functional MRI
Study NCT05288439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive battery with quality-of-life assessment
Description: Cognitive and quality of life assessments performed by a trained neuropsychologist
Study NCT06108206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: Each patient will undergo a brain MRI at the following time points:~1. Baseline- within 2 weeks prior to the start of chemo-RT,~2. Week #1- on Fractions # 4 or 5~3. Week #2- between Fractions # 6-10 (at least 5 days after the Week 1 MRI)~4. Week #3- between Fractions # 11-15 (at least 5 days after the Week 2 MRI)~5. Week #4- between Fractions # 16-20 gadolinium contrast (at least 5 days after the Week 3 MRI)~6. Week #5- on Fractions # 24 or 25 (after the start of the Conedown)~7. Week #6- +/- 3 days of Fraction #30 (end of RT)~Patients receiving hypofractionated radiotherapy will undergo a brain MRI at the following time points:~1. Baseline- within 2 weeks prior to the start of your standard of care chemotherapy radiation treatment (chemo-RT),~2. Week #1 - on Fractions #4 or 5~3. Week #2 - between Fractions #6-10 (at least 5 days after the Week 1 MRI)~4. Week #3 - between Fractions #11-15 (at least 5 days after the Week 2 MRI)
Study NCT05119101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamedotomidine added to Magnesium sulfate
Description: we will give dexamedotomidine and mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
Study NCT05119101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: we will give mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
Study NCT05508919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: EMG, RESP, and TEMP Biofeedback Training
Study NCT05508919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Writing Sessions
Description: The subjects will be asked to take three 20-minute writing sessions and write about the given control topic about their daily events of the past week
Study NCT06068036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth intervention: HEARTS technical package + activity monitor (Smartwatch Mi Band 7®)
Description: Telehealth intervention involving the HEARTS technical package and the use of Smartwatch Mi Band 7® activity monitor. The HEARTS technical package presents the 5As brief intervention (Ask, Advise, Assess, Assist, Arrange) to promote physical activity participation. Participants will receive a physical activity monitor (as instructed in the HEARTS technical package) and will be monitored by telephone call, once a week, in order to reinforce successes and identify solutions to difficulties (as instructed in the HEARTS technical package) to practice physical activity. These individuals will undertake a 12-week intervention program. In the first week, individuals will perform the first four steps of the 5As brief intervention in person, where they will be instructed on how to use the physical activity monitor, they will receive a diary of regular physical activity practice, will be guided on how to fill it out, and will schedule the best times to receive the weekly telephone call.
Study NCT06068036 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth intervention: HEARTS technical package
Description: The same intervention as the experimental group, but without the additional use of the physical activity monitor (Smartwatch Mi Band 7®).
Study NCT05710809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted specialized physical group-based exercise and Comprehensive Geriatric Assessement
Description: Vestibular rehabilitation, balance- and progressive resistance training for three months' three times/week and Comprehensive Geriatric Assessement including corresponding interventions
Study NCT05844241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music and Theta Auditory Beat Stimulation
Description: Listening to music and ABS for 30 minutes.
Study NCT05844241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audiobooks
Description: Listening to audiobooks for 30 minutes
Study NCT05615207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery as compared to physical practice for balance tasks
Description: We will investigate if using motor imagery (mentally imagining and practicing a task) as a means of balance training is as effective as physical practice
Study NCT05615207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Imagery as compared to physical practice for balance tasks
Description: We will investigate if using motor imagery (mentally imagining and practicing a task) as a means of balance training is as effective as physical practice
Study NCT05615740 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Optical coherence tomography (OCTA)
Description: OCTA can detect the passage of individual blood elements (mostly erythrocytes) through capillaries and larger vessels in real-time
Study NCT05281198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tart cherry juice
Description: 2, 8oz bottles of Montmorency tart cherry juice daily; 8oz taken in AM, 8oz taken in PM
Study NCT05281198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2, 8oz bottles of placebo juice daily; 8oz taken in AM, 8oz taken in PM
Study NCT05076890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15 mg/g Full Spectrum Hemp Extract
Description: HPMC capsules containing full spectrum standardized hemp extract in liquid form.
Study NCT05076890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50 mg/g Full Spectrum Hemp Extract
Description: HPMC capsules containing full spectrum standardized hemp extract in liquid form.
Study NCT05627024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% Oxygen
Description: Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 30%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation, however when intraoperative oxygen saturation is less than 92% the manual lung recruitment maneuver will be done too. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
Study NCT05627024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 60% Oxygen
Description: Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 60%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
Study NCT04760405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Easy
Description: Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
Study NCT04829916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-035
Description: Multiple dosing during 48 hours following cardiac surgery
Study NCT04829916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dosing during 48 hours following cardiac surgery
Study NCT05496569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 capsule
Description: TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor
Study NCT05496569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQB3616 placebo
Description: Placebo
Study NCT05133765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump
Description: Alterations in insulin pump therapy or carbohydrate consumption
Study NCT05180071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEMA elbow system
Description: Total elbow replacement
Study NCT06195397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-Based Education intervention
Description: A total of 12 hours of Evidence-Based Education intervention was applied to students in the intervention group, spread over 7 sessions.
Study NCT05365204 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near infrared fluorescence navigated sentinel lymph node mapping
Description: Patient will undergo sentinel lymph node biopsy with near infrared fluorescence navigation. The dosage of ICG will not exceed 2.5 mg in total, and the volume of the assigned solvent will not exceed 5 mL in total.
Study NCT05365204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near infrared fluorescence navigated sentinel lymph node mapping
Description: Patient will undergo sentinel lymph node biopsy with near infrared fluorescence navigation. The dosage of ICG will not exceed 2.5 mg in total, and the volume of the assigned solvent will not exceed 5 mL in total.
Study NCT06049056 — intervention group
Intervention type: OTHER
Intervention: Invitation
Description: During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,
Study NCT04935528 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: serology and ELISPOT test
Description: 27 mL blood sample to study the humoral and the cellular immune response
Study NCT04935528 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: serology
Description: 7 mL blood sample to study the humoral response
Study NCT06367465 — intervention group
Intervention type: DRUG
Intervention: Glecaprevir-pibrentasvir
Description: Glecaprevir-pibrentasvir 100 mg / 40 mg 3 tab orally (PO) once daily for 56 days.
Study NCT05112692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone Tablets
Description: first arm will be coadministered gonadotrophins with 20mg dydrogesterone till day of trigger second arm will be subjected to fixed GnRH antagonist protocol then will do Freeze All in both arms then frozen embryo transfer next cycle
Study NCT05112692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetrorelix 0.25mg
Description: In the fixed GnRH antagonist protocol, daily s.c. administration of Cetrotide 0.25 mg will be initiated at 6th day of stimulation. HMG (150-225IU) will be administered daily from menstrual cycle day 3.
Study NCT05112692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human menopausal gonadotropin
Description: (150-225IU) will be administered daily from menstrual cycle day 3 till day ot trigger
Study NCT05112692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triptorelin 0.1 mg
Description: When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
Study NCT06525337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STANDARDCARE (STAND) group
Description: Will receive a device and health coaching
Study NCT06525337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONTROL (CON) group
Description: Will not use any devices or receive health coaching
Study NCT05112692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin
Description: When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
Study NCT05112692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryopreservation
Description: All of the follicles greater than 10mm in diameter will be aspirated. The oocytes are inseminated approximately 4-6hours after follicular aspiration by a conventional IVF method or intracytoplasmic sperm injection, based on the sperm quality On day 3, high quality embryos are cryopreserved by means of vitrification
Study NCT05112692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate and progesterone
Description: Endometrium will be prepared using step-up oral estrogen protocols. On day 14 of estrogen administration, endometrial thickness will be assessed and serum progesterone level will be measured, with cycles to be cancelled according to the arbitrary thresholds of 7.0 mm and 1.5 ng/mL, respectively. Progesterone administration will be started on the morning (am) of day 15, with the start date of progesterone and the day of blastocyst cryopreservation used to coordinate the day of FET
Study NCT05635110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.
Study NCT06337799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Research Pharmacist
Description: The goal of this intervention is to determine if allied health professionals will improve blood pressure in new mothers.
Study NCT05635110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Tablets for oral administration.
Study NCT05635110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Capsules for oral administration.
Study NCT05893693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological
Description: CT0594CP
Study NCT04839900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proactive iCCM
Description: CHWs in the proactive iCCM intervention arm will conduct weekly visits of all households in their communities to detect children \< 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. People with fever or history of fever in the past 48 hours, or any person with symptoms suggestive of malaria (chills, headache, muscle ache, fatigue, etc), will receive an RDT; those with positive results will be defined as confirmed malaria cases, and will receive the first line antimalarial. Any child under 5 years with diarrhea will be treated with oral rehydration solution (ORS) and zinc, and any child meeting diagnostic criteria for pneumonia will receive the first line antibiotic recommended per national iCCM policy. If the CHW does not have the indicated therapy on hand, the patient will be referred for treatment.
Study NCT05700552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skin to skin contact
Description: For skin-to-skin contact (TTT), the newborn is placed naked on the mother's bare chest in the prone (prone) position, the newborn's abdomen and chest are in contact with the mother's skin, and the newborn's head is turned to the side so that the airway remains open.
Study NCT05826964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI+CDK4/6i
Description: Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:~* AI: Anastrozole, Letrozole or Exemestane~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib
Study NCT05826964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SERD+CDK4/6i
Description: Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:~* SERD: Fulvestrant~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib
Study NCT05826964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mTOR inhibitor + AI
Description: Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with AI therapy (Exemestane) in Step 2 Arm 2 and Step 3. mTOR inhibitor + AI therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Study NCT05719155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379
Description: 1 tablet administration under fed condition
Study NCT05719155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759+D745+D150
Description: 3 tablet coadministration under fed condition
Study NCT05826964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mTOR inhibitor + SERD
Description: Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with SERD therapy (Fulvestrant), in Step 2 Arm 2 and Step 3. mTOR inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Study NCT05826964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mTOR inhibitor + Selective estrogen receptor modulator
Description: Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with selective estrogen receptor modulator therapy (Tamoxifen) in Step 2 Arm 2 and Step 3. mTOR inhibitor + Selective estrogen receptor modulator therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Study NCT05826964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K inhibitor + SERD
Description: Participants will receive standard of care one PI3K inhibitor therapy (Alpelisib), in combination with SERD therapy (Fulvestrant) in Step 2 Arm 2 and Step 3. PI3K inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Study NCT05826964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K inhibitor + AI
Description: Participants will receive standard of care a PI3K inhibitor therapy (Alpelisib), in combination with an AI therapy (Letrozole) in Step 2 Arm 2 and Step 3. PI3K inhibitor + AI therapy administered as one of the available options for early switch from SERD+CDk4/6i therapy in administered in Step 1.
Study NCT05826964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy administered standard of care as an alternative therapy in Step 2 Arm 2 and Step 3.
Study NCT05826964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral SERD
Description: Participants will receive standard of care oral SERD therapy (Elacestrant) in Step 2 Arm 2 and Step 3. Oral SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Study NCT05077735 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study NCT05077735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05077735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05077735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography and Computed Tomography Scan
Description: Undergo PET-CT scan
Study NCT06166199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT combined with resistance training
Description: Patients with SLE will undergo supervised HIIT on an ergometercycle, 4 x 4 minutes interval, (85-90% of maximal heart rate in 4 minutes and lower intensity for another 4 minutes etc). The HIIT is combined with resistance exercises for upper and lower extremity. In total the training takes around 50 minutes per occasion and will be performed 2 times/week, for 3 months. In addition, the patients will exercise, according to the program, by themselves once a week.~Between months 3 and 6 the patients exercise by themselves, 3 times/week, with video-call/telephone support from a physiotherapist once a week.